Part of this review was presented at The 3rd International Forum of the 98th General Meeting of the Japanese Society of Gastroenterology.
Using commercial quantitative assays, quantitative hepatitis B surface antigen (qHBsAg) has improved our understanding and management of chronic hepatitis B (CHB). The HBsAg level is highest in the immune tolerance phase, starts to decline during the immune clearance phase, and decreases slowly but progressively after hepatitis B e antigen (HBeAg) seroconversion. The HBsAg level is lowest in individuals with an inactive carrier state but higher in those who develop HBeAg-negative hepatitis. It has been shown that a reduction of HBsAg by 1 log IU/mL or more reflects improved host immune control of HBV infection. A combination of HBsAg <1000 IU/mL and HBV-DNA <2000 IU/mL can identify a 3-year inactive state in a genotype D HBeAg-negative carrier population. In the Asian-Pacific region, where HBV genotypes B and C are dominant, HBsAg levels of ≤10–100 IU/mL predict HBsAg loss over time. As to the prediction of disease progression, low-viremic carriers with HBsAg >1000 IU/mL have been shown to be at higher risks of HBeAg-negative hepatitis, cirrhosis, and hepatocellular carcinoma than those with HBsAg <1000 IU/mL. Although qHBsAg has been widely used in CHB patients receiving pegylated interferon therapy, the HBsAg decline is slow and does not correlate with HBV-DNA levels during nucleos(t)ide analogue (NUC) therapy. However, a rapid HBsAg decline during NUC therapy may identify patients who will finally clear HBsAg. A 6- to 12-monthly assessment of HBsAg level could be considered during NUC therapy. Taking these lines of evidence together, qHBsAg can complement HBV-DNA levels to optimize the management of CHB patients in our daily clinical practice.
Blumberg BS, Sutnick AI, London WT. Hepatitis and leukemia: their relation to Australia antigen. Bull N Y Acad Med. 1968;44:1566–86. PubMed
Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European concerted action on viral hepatitis (EUROHEP). Am J Gastroenterol. 1998;93:896–900. PubMedCrossRef
McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759–68. PubMed
Kim JH, Lee JH, Park SJ, Bae MH, Do Kim Y, Kim JK, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology. 2008;55:578–81. PubMed
Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141(517–525):e2.
Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, et al. A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels three years before HBsAg seroclearance. Hepatology. 2012;56:812–9.
Lik-Yuen Chan H, Lai-Hung Wong G, Tse CH, Chan HY, Wai-Sun Wong V. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis. 2011;204:408–14. CrossRef
Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje U, Lu SN, et al. Quantitative hepatitis B surface antigen levels are significant independent predictors of HBV DNA and HBsAg seroclearance in chronic hepatitis B. Hepatology. 2011;54:Abstract 239.
Chang MH, Chiu YC, Wu JF, Lin CY, Ni YH, Chen HL, et al. Spontaneous clearance of hepatitis B surface antigen during the natural history of chronic hepatitis B virus infection. Hepatology. 2011;54:Abstract 731.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.
Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.
Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142(1140–1149):e3. PubMed
Chen CJ, Lee MH, Jessica L, Ricard B-U, Jen CL, Uchenna I, et al. Quantitative serum levels of hepatitis B virus DNA and surface antigen are independent risk predictors of hepatocellular carcinoma. Hepatology. 2011;54:Abstract 1095.
Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141:1240–8, 1248 e1–2.
Seto WT, Wong KH, Fung J, Hung FN, Yuen CH, Tong T, et al. Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Hepatol Int. 2012 (in press). doi: 10.1007/s12072-012-9373-4.
Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. 2012 (In press). doi: 10.1007/s12072-011-9280-0.
Gane E, Heathcote EJ, Marcellin P, Dusheiko G, Jacobson I, de Man R, et al. HBsAg kinetics of decay and baseline characteristics of HBsAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment. J Hepatol. 2010;52(Suppl 1):S388. CrossRef
- Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog
- Springer Japan
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II